Examining Selinexor Role in RRMM Treatment

Noa Biran, MD, discusses how selinexor targets nuclear export, inducing apoptosis in multiple myeloma cells. Its synergistic potential with approved agents makes it suitable across refractory cases, bridging therapy options and improving patients' quality of life.

EP: 1.Addressing Unmet Needs in Relapsed/Refractory Multiple Myeloma

EP: 2.Breakthrough Agents Reshaping RRMM Treatment Landscape

EP: 3.Overview of the BOSTON Trial Evaluating a Selinexor Triplet Regimen

Now Viewing

EP: 4.Examining Selinexor Role in RRMM Treatment

EP: 5.STOMP Study: Effective Selinexor Regimen in Multitherapy Combo

EP: 6.Sequencing Selinexor With Novel BCMA Therapies

EP: 7.Multiple Myeloma: Evolving Therapies and Patient Well-Being

EP: 8.Optimizing Novel Treatment Options in Relapsed/Refractory Multiple Myeloma

Recent Videos

Related Content

---

Optimizing Novel Treatment Options in Relapsed/Refractory Multiple Myeloma

Russ Conroy

March 4th 2024

Article

Noa Biran, MD, speaks about recently approved bispecific therapies and current trials that may impact the standard of care in relapsed/refractory multiple myeloma.

Related Content

---

Optimizing Novel Treatment Options in Relapsed/Refractory Multiple Myeloma

Russ Conroy

March 4th 2024

Article

Noa Biran, MD, speaks about recently approved bispecific therapies and current trials that may impact the standard of care in relapsed/refractory multiple myeloma.